Fundraising FoxAdjuvance Technologies
New York, US · Delaware corporation
Find your way into Adjuvance Technologies
Sign up to find every way you can get introduced to Adjuvance Technologies
- Your email: who you already know at Adjuvance Technologies, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Adjuvance Technologies team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
CF
Christopher FrigonExecutive
JG
Jeffrey GardnerExecutive
TM
Tyler MartinExecutive
PL
Phil LivingstonNamed on SEC filing
Board
MG
Mary GinBoard director
JG
John GalloBoard director
GP
Gregory PolandBoard director
Reported raises · per SEC filings
Form D private placements$13.4M disclosed across 2 rounds · 2015–2019
▶$10.7MraisedNov 2019 · 28 investors · BiotechnologyRule 506(b)
▶$10.7MraisedNov 2019 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac ChengDirector
- Ken KelleyDirector
- Stephen DillyDirector
- J. Tyler MartinExecutive Officer, Director
- Offering amount
- $24.7M
- Amount sold
- $10.7M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedNov 2016 · 15 investors · BiotechnologyRule 506(b)
▶$2.7MraisedNov 2016 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher FrigonExecutive Officer
- Jeffrey GardnerExecutive Officer
- Mary GinDirector
- Gregory PolandDirector
- Tyler MartinExecutive Officer, Director
- Phil LivingstonDirector
- John GalloDirector
- Offering amount
- $7M
- Amount sold
- $2.7M
- Minimum investment
- $25K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $527.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $223K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- How much funding has Adjuvance Technologies raised?
- Adjuvance Technologies has disclosed $13.4M raised across 2 rounds.
- Where is Adjuvance Technologies headquartered?
- Adjuvance Technologies is headquartered in New York, US.